The effect of calcium dobesilate on nonproliferative diabetic retinopathy: a controlled study.
Two independent, double-masked, controlled studies were made to evaluate the efficacy of calcium dobesilate for the treatment of nonproliferative diabetic retinopathy. Forty-two patients underwent a six-month crossover evaluation while receiving calcium dobesilate (750 mg per day) and placebo in random order. Thirty-six patients received calcium dobesilate (1,000 mg per day) or placebo for one year. Evaluation by clinical examination, fluorescein angiography, angiography, and fundus photography failed to demonstrate any beneficial effect of calcium dobesilate.
D000328:Adult; D000783:Aneurysm / Q000188:drug therapy; D001557:Benzenesulfonates / Q000627:therapeutic use*; D002123:Calcium Dobesilate / Q000494:pharmacology / Q000627:therapeutic use*; D002198:Capillary Fragility / Q000187:drug effects; D002986:Clinical Trials as Topic; D003930:Diabetic Retinopathy / Q000188:drug therapy*; D004311:Double-Blind Method; D005122:Exudates and Transudates / Q000187:drug effects; D005451:Fluorescein Angiography; D006801:Humans; D010919:Placebos; D011859:Radiography; D012166:Retinal Hemorrhage / Q000188:drug therapy; D012171:Retinal Vessels / Q000000981:diagnostic imaging
D001557:Benzenesulfonates; D010919:Placebos; D002123:Calcium Dobesilate